AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 4 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for FluMist (influenza virus vaccine live, intranasal), a live attenuated influenza vaccine delivered as a nasal mist.
FDA is requesting clarification and additional information relating to data previously submitted. No additional clinical trials have been requested.
"As expected, we received a complete response letter from the FDA requesting additional information relating to our FluMist application," said David M. Mott, MedImmune's ...